Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug interactions with thrombolytic agents. Current perspectives

A de Boer1, J M van Griensven

  • 1Department of Pharmacoepidemiology and Pharmacotherapy, Faculty of Pharmacy, Utrecht University, The Netherlands.

Clinical Pharmacokinetics
|April 1, 1995
PubMed
Summary

Drug interactions with thrombolytic agents like alteplase and saruplase can alter their effectiveness and safety. Physicians must understand how coadministered drugs and hemodynamic changes affect these critical treatments for thromboembolic diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A method to measure renal inner medullary perfusion using MR renography.

Magma (New York, N.Y.)·2025
Same author

Adults born prematurely prefer a periviability guideline that considers multiple prognostic factors beyond gestational age.

Acta paediatrica (Oslo, Norway : 1992)·2023
Same author

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.

ESMO open·2023
Same author

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC.

BMC medical research methodology·2023
Same author

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC.

BMC medical research methodology·2023
Same author

Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?

Breast (Edinburgh, Scotland)·2022

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Interactions

Background:

  • Thrombolytic agents are crucial for acute thromboembolic diseases, particularly acute myocardial infarction (AMI).
  • These drugs, including alteplase and saruplase, have narrow therapeutic windows, making plasma concentration critical.
  • Drug interactions and hemodynamic factors can significantly impact their pharmacokinetics and pharmacodynamics.

Purpose of the Study:

  • To review anticipated drug interactions with thrombolytic agents.
  • To discuss the influence of hepatic blood flow (HBF) on the pharmacokinetics of high-clearance thrombolytics like alteplase and saruplase.
  • To highlight the role of circulatory changes in potential drug-drug interactions.

Main Methods:

  • Review of pharmacological knowledge of thrombolytic agents.

Related Experiment Videos

  • Analysis of general mechanisms of pharmacokinetic drug interactions.
  • Evaluation of indirect evidence from clinical observations and animal studies.
  • Discussion of hemodynamic factors affecting drug clearance.

    • Main Results:

    • Interactions with alteplase and saruplase are expected due to their high clearance, dependent on hepatic blood flow (HBF).
    • Pharmacological agents altering HBF can change thrombolytic plasma concentrations.
    • Cardiogenic hemodynamic failure can impair liver perfusion, affecting thrombolytic clearance.
    • Pharmacodynamic interactions, especially with antithrombotics and antiplatelets, increase bleeding risk.

    Conclusions:

    • Physicians must be aware of the benefits and risks of drug interactions with thrombolytic agents.
    • Altered HBF, induced by drugs or hemodynamic failure, is a primary mechanism affecting alteplase and saruplase pharmacokinetics.
    • Optimizing treatment strategies requires further evaluation of drug interactions to mitigate bleeding complications.